Have questions about A Race Against Blindness or our fundraiser sweepstakes? This hub page gathers all five articles from our Trust, Transparency, and Our Mission series — covering our story, our legal compliance, our real winners, and how you can verify us.

Blog Series Hub: Trust, Transparency, and Our Mission: The Truth About A Race Against Blindness

Article 1-5 linked here.

A groundbreaking Phase 2 trial has shown the first-ever vision improvements in people with Stargardt disease — a condition with no approved treatment. Nanoscope Therapeutics’ gene-agnostic MCO-010 therapy produced meaningful gains in vision without serious side effects, paving the way for a pivotal Phase 3 trial starting in 2025.

Blog Series: Trust, Transparency, and Our Mission: The Truth About A Race Against Blindness

Article 5: Our Commitment to Transparency & How You Can Verify Us

Blog Series: Trust, Transparency, and Our Mission: The Truth About A Race Against Blindness

Article 4: Why We Use Fundraiser Sweepstakes to Advance Our Mission

Blog Series: Trust, Transparency, and Our Mission: The Truth About A Race Against Blindness

Article 3: Winners & Where to Find Them